Collegium Pharmaceutical Inc (COLL)

[floblu14]

Analysts' Upgrades -

A. Cantor upgrades Collegium on revenue diversification from deal 16:28 COLL, BDSI Cantor Fitzgerald analyst Brandon Folkes upgraded Collegium Pharmaceutical (COLL) to Overweight from Neutral with a price target of $26, up from $18, following the company's acquisition of BioDelivery Sciences (BDSI). The upgrade is driven by the diversification in revenue in which the deal brings, as well as a footprint in the adjacency neurology category, Folkes tells investors in a research note. The analyst believes Collegium's newly diversified revenue streams and therapeutic focus are both "multiple enhancing." Folkes adds that while his overall concerns with the branded Xtampza and OxyContin market decline has not subsided, the start of 2022 offers "some hope that the decline could stabilize this year."

Read more at:
https://thefly.com/n.php?id=3458996

B. Collegium Pharmaceutical price target raised to $29 from $26 at H.C. Wainwright

C. Collegium Pharmaceutical price target raised to $34 from $28 at Needham 07:16 COLL, BDSI